Does a phased approach enhance outcomes for trauma-focused cognitive therapy for complex posttraumatic stress disorder?
| ISRCTN | ISRCTN13869856 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13869856 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Integrated Research Application System (IRAS) | 309119 |
| Protocol serial number | CPMS 58088, IRAS 309119, Protocol version 1 11th November 2022 Internal Reference (Sponsor – Queen’s University Belfast): B22/21 |
| Sponsor | Queen's University Belfast |
| Funder | National Institute for Health and Care Research |
- Submission date
- 02/03/2023
- Registration date
- 07/03/2023
- Last edited
- 16/07/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Plain English summary of protocol
Background and study aims
Cognitive Therapy for Posttraumatic Stress Disorder (CT-PTSD) is a NICE-recommended psychological therapy that has been shown to be effective and acceptable to patients in many research studies and clinical audits. Complex PTSD is a new diagnosis introduced into the diagnostic manual of the World Health Organisation (ICD-11) to characterise people who have unwanted memories of traumas, avoidance of reminders, high arousal and problems with emotion regulation, a negative view of themselves and problems maintaining relationships. This study aims to investigate how effective CT-PTSD is in clients treated across a wide range of services across Northern Ireland and England. The study will compare the delivery of CT-PTSD with and without a phased element. In one group, the treatment involves the immediate provision of CT-PTSD, which is adapted individually to each patient, and in the other group CT-PTSD is provided after eight sessions of compassionate resilience training (phased CT-PTSD). The study will consider whether both approaches work equally well or whether there are advantages in providing a phased approach or a non-phased approach for some groups of clients.
Who can participate?
Patients aged 18 years and above with complex PTSD
What does the study involve?
Participants who are eligible and wish to take part in the study will (after consent) be randomly allocated to one of two groups (phased or non-phased). Treatment in the trial involves 24 treatment sessions and regular assessments that measure progress during therapy and at follow-up time points. Questionnaires will be completed at the eligibility assessment, after 9 and 17 weeks of treatment, at the end of therapy (26 weeks) and 3 months (39 weeks) and 6 months after the end of therapy (52 weeks). These sets of questionnaires will take about 30 to 60 minutes to complete. Some of the questionnaires will also be given regularly during treatment to help the therapist with planning treatment sessions. At 2 and 10 weeks, participants will be asked some brief questions about their thoughts on the treatment. In addition, independent assessors will interview participants at the eligibility stage, end of treatment (26 weeks) and 6 months later (52 weeks). In total, your involvement with the study will be for 1 year.
What are the possible benefits and risks of participating?
Participants will be offered an evidence-based treatment for PTSD with or without a phased element under the supervision of experienced supervisors and trainers in CT-PTSD and Compassionate Resilience Training. Participants will be able to avail of one of these therapies under the controlled scrutiny and high standards required for a randomised controlled trial. Participation in this study also has the potential to make a valuable contribution to existing research on treatments for Complex PTSD.
With regard to risk, participant wellbeing is paramount and protocols are in place to ensure participants feel safe and support. Should a participant find any aspects of the study distressing, there will be a discussion around how the therapy will be adapted around the individual’s needs.
Where is the study run from?
The PHASE-CPTSD study is a collaboration between Queens University Belfast, the University of Oxford and ten HSC and NHS Foundation Trusts across Northern Ireland and England (UK)
When is the study starting and how long is it expected to run?
June 2020 to September 2025
Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)
Who is the main contact?
1. Dr Michael Duffy, michael.duffy@qub.ac.uk
2. Prof. Anke Ehlers, anke.ehlers@psy.ox.ac.uk
Contact information
Principal investigator
Queen's University Belfast
69 University Street
Belfast
BT7 1HL
United Kingdom
| Phone | +44 (0)2890973298 |
|---|---|
| michael.duffy@qub.ac.uk |
Principal investigator
University of Oxford
Department of Experimental Psychology
Centre for Anxiety Disorders and Trauma
The Old Rectory
Paradise Square
Oxford
OX1 1TW
United Kingdom
| Phone | +44 (0)1865618600 |
|---|---|
| anke.ehlers@psy.ox.ac.uk |
Public
Queen's University Belfast
69 University Street
Belfast
BT& 1HL
United Kingdom
| Phone | +44 (0)2890913168 |
|---|---|
| nina.oneill@qub.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicentre randomized controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Does a PHASEd approach enhance outcomes for trauma-focused cognitive therapy for Complex Post-Traumatic Stress Disorder? |
| Study acronym | PHASE-CPTSD |
| Study objectives | 1. Is phased Cognitive Therapy for Posttraumatic Stress Disorder (CT-PTSD) superior to non-phased CT-PTSD in terms of acceptability, compliance and satisfaction with treatment? 2. Is phased CT-PTSD superior to non-phased CT-PTSD in improving symptoms of CPTSD, depression, anxiety, disability, well-being, and quality of life? 3. Is phased CT-PTSD cost-efficient compared to non-phased CT-PTSD in terms of cost per participant with a clinical improvement in PTSD symptoms and costs per quality-adjusted life year (QALY) gained? |
| Ethics approval(s) | Approved 22/01/2023, South Central - Berkshire B Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)2071048276; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0466 |
| Health condition(s) or problem(s) studied | Complex Post-Traumatic Stress Disorder (CPTSD) |
| Intervention | Approximately even numbers are allocated to the two treatment arms, phased CT-PTSD and non-phased CT-PTSD; allocation is stratified based on site, CPTSD symptom severity, age at main trauma (<18 years vs 18 years and above) and need for a translator (yes vs no); the randomization sequence is not visible to the research staff who generate the treatment randomization with the programme to ensure allocation concealment. CT-PTSD is a NICE-recommended first-line treatment for PTSD. It addresses distressing trauma memories and their meanings as well as unhelpful ways of coping. 24 sessions will be offered. Outcomes will be assessed at baseline and 9, 17, 26, 39 and 52 weeks after randomization. In phased CT-PTSD, 16 sessions of this treatment are offered after 8 weeks of compassionate resilience training. Outcomes will be assessed at the same time points as for non-phased CT-PTSD. |
| Intervention type | Behavioural |
| Primary outcome measure(s) |
1. Complex PTSD symptom severity, as assessed by the International Trauma Questionnaire (ITQ) at 26 weeks post-randomisation. |
| Key secondary outcome measure(s) |
1: Depression measured using the Patient Health Questionnaire (PHQ-9) at weeks 9, 17, 26, 39 and 52 |
| Completion date | 30/09/2025 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 350 |
| Total final enrolment | 117 |
| Key inclusion criteria | 1. Aged 18 years and above 2. Willing and able to provide informed consent 3. Meets ICD-11 diagnostic criteria for CPTSD as determined by the International Trauma Interview (ITI) 4. CPTSD is the main psychological problem needing treatment 5. Willing to be randomized to a treatment arm 6. If taking psychotropic medication, the dose must be stable for at least 1 month before randomization to a treatment arm 7. If currently receiving psychological therapy for CPTSD, this treatment must have ended before being randomized to a treatment arm |
| Key exclusion criteria | 1. History of psychosis 2. Current substance dependence 3. Acute serious suicide risk |
| Date of first enrolment | 01/04/2023 |
| Date of final enrolment | 30/06/2024 |
Locations
Countries of recruitment
- United Kingdom
- England
- Northern Ireland
Study participating centres
5 Greenmount Avenue
Ballymena
Co. Antrim
BT43 6DA
United Kingdom
Altnagelvin Area Hospital Site
Glenshane Road
Londonderry
BT47 6SB
United Kingdom
Hospital
68 Lurgan Road
Portadown
Co. Armagh
BT63 5QQ
United Kingdom
19/21 Magheralave Road
Co. Antrim
BT28 3BP
United Kingdom
Saintfield Road
Belfast
BT8 8SG
United Kingdom
Osney Mead
Oxford
OX2 0ES
United Kingdom
Prospect House
Crendon Street
High Wycombe
HP13 6LA
United Kingdom
London
N7 6ER
United Kingdom
St Pancras Hospital
4 St Pancras Way
NW1 0PE
United Kingdom
2nd Floor
75-79 Miles Rd
Mitcham
CR4 3DA
United Kingdom
1st Floor
6 Stanley Park Road
Wallington
SM6 0EX
United Kingdom
Elizabeth Newton Building
Trinity Building, Springfield University Hospital
15 Springfield Drive
London
SW17 0YF
United Kingdom
Whiteknights
Reading
RG6 6BZ
United Kingdom
Whiteknights
Reading
RG6 6BZ
United Kingdom
St Albans
AL3 5TL
United Kingdom
Springwood Drive
Braintree
CM7 2YN
United Kingdom
Saffron House
Easton Street
High Wycombe
HP11 1NH
United Kingdom
The Residence building
St Pancras Hospital
4 St Pancras Way
London
NW1 0PE
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The data-sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Protocol file | version 3.0 | 25/11/2024 | 09/01/2025 | No | No |
| Protocol file | version 4 | 14/01/2025 | 16/07/2025 | No | No |
Additional files
- ISRCTN13869856_Protocol_V3.0_25Nov2024.pdf
- Protocol file
- ISRCTN13869856_PROTOCOL_V4_14Jan25.pdf
- Protocol file
Editorial Notes
16/07/2025: Protocol version 4 (not peer reviewed) added.
09/01/2025: The following changes were made:
1. Protocol version 3.0 (not peer reviewed) added.
2. The recruitment end date was changed from 31/08/2024 to 30/06/2024.
3. The total final enrolment was added.
20/04/2023: The trial participating centre Ni Ambulance Service Health and Social Care Trust was changed to Belfast Health and Social Care Trust.
04/04/2023: The trial participating centre Step 4 Psychological Therapies was removed and South Bucks Psychological Therapies and South Camden iCope were added.
06/03/2023: Trial's existence confirmed by the South Central - Berkshire B Research Ethics Committee.